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ABSTRACT
Background: Liver biopsy is the gold standard in evaluating inflammation and fibrosis in autoimmune
hepatitis.
Aims: In search of non-invasive follow-up tools in autoimmune hepatitis, we evaluated 31phosphorus
magnetic resonance spectroscopy (31P MRS).
Methods: Twelve consecutive AIH patients (mean age 42.8 years, 10 women) underwent liver biopsy,
routine laboratory liver function tests, which were compared to findings in 31P MRS and transient elas-
tography (TE).
Results: Phosphoenolpuryvate (PEP) correlated with the grade of inflammation (r¼ 0.746, p¼ .005) and
thromboplastin time (r¼ 0.592, p¼ .043). It also differentiated patients with active inflammation from
patients without (t¼ 3.781, p¼ .009). There was no correlation between PEP and aminotransferase or
immunoglobulin G levels.
The phosphoethanolamine (PE)/phosphocholine (PC) ratio, PE/glyserophosphoethanolamine (GPE) ratio
and PC/[total phosphomonoester (PME)þphosphodiester (PDE)] ratios correlated with immunoglobulin
G (r¼ 0.764, p¼ .006; r¼ 0.618, p¼ .043; and r¼0.636, p¼ .035, respectively).
PME/PDE and PE/GPE correlated with fibrosis (r¼ 0.668, p¼ .018 and r¼ 0.604, p¼ .037). PE/GPE also
differentiated F3 from F0-2 patients (t¼ 3.810, p¼ .003).
Phosphorus metabolites did not correlate with TE results and TE did not correlate with liver histology
or laboratory parameters.
Conclusions: 31P MRS seems to detect active inflammation and advanced fibrosis in AIH patients. TE
was ineffective in fibrosis quantification.
Abbreviations: AC: anabolic charge; AIH: autoimmune hepatitis; Alb: albumin; ALP: alkaline phosphat-
ase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CI: confidence interval; F: fibrosis;
G: grade; GPE: glyserophosphoethanolamine; GPC: glycerophosphocholine; IgG: Immunoglobulin G; MR:
magnetic resonance; NADPH: nicotinamide adenine dinucleotide phosphate; NPV: negative predictive
value; ; NTP: nucleotide triphosphate; PC: phosphocholine; PC: phosphocholine; PDE: total phospho-
diester level; PE: phosphoethanolamine; PEP: phosphoenolpuryvate; PEP/PtdC: phosphoenolpyruvate/
phosphatidylcholine; Pi: phosphorus; PME: total phosphomonoester level; 31P MRS: 31phosphorus mag-
netic resonance spectroscopy; PPV: positive predictive value; PtdC: phosphatidylcholine; TE: transient
elastography; TT: thrombolastin time; UDPG: uridine diphosphoglucose
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The goal of therapy of autoimmune hepatitis is serological
and histological remission in order to prevent fibrosis pro-
gression and cirrhosis development and to control inflamma-
tion-induced symptoms. With standard therapy (prednisolone
or prednisolone in combination with azathioprine), this is
achieved in most patients [1] with up to 89% with 10 years
survival. Liver biopsy is regarded to be important for diagno-
sis, but in addition, it provides important information about
the disease prognosis, as proposed by the American
Association for the Study of Liver Disease and the British
Society of Gastroenterology [1,2]. The role of follow-up
biopsies is more controversial. Both of these societies recom-
mend follow-up biopsies to confirm remission during main-
tenance therapy and prior to drug withdrawal. Inflammation
activity during therapy can be estimated by alanine amino-
transferase (ALT) and immunoglobulin G (IgG) levels, but
histological inflammation resolves more slowly than the
laboratory tests become normal [3]. Also, a proportion of
patients have ongoing active inflammation despite of normal
laboratory values, which can render them for progressive
fibrosis development. These patients are also likely to relapse
after treatment discontinuation [3,4]. It has been shown that
histological cirrhosis seems to be partially reversible in some
AIH patients. In paired liver biopsies, fibrosis/cirrhosis
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category was demonstrated to improve during therapy in
57% (16/28) of patients including 9/14 patients with reso-
lution of nodular fibrosis/cirrhosis [5].
31Phosphorus magnetic resonance spectroscopy of the
liver (31P MRS) has been evaluated in various liver diseases
and has shown to be promising [6,7] in evaluating progres-
sive liver disease, while being able to show both fibrosis and
inflammation in the liver. Anabolic charge (AC, elevation of
PME and decreased PDE) has been shown to rise in a fibrotic
liver and also separate advanced from mild fibrosis in diffuse
liver disease [8,9]. What makes this method ideal is that it
has been reported to predict both fibrosis and inflammation,
both being important when making treatment decisions
regarding AIH patients. It is also non-invasive.
Transient elastography (TE) [10] has been evaluated in
autoimmune hepatitis: In two series, comprising a total of 28
AIH patients, the authors concluded that TE was effective in
finding patients with Metavir [11] fibrosis two patients,
although these studies reported only the pooled results with
other non-viral hepatitis patients [12,13]. Case reports have
also demonstrated that in AIH, inflammation results in dispro-
portionally high TE levels, which normalise after treatment
initiation [14]. TE finds cirrhosis reliably after six months of
treatment with a cut-off of 16 kilopascals but is less reliable
in non-cirrhotic patients [15] and prior to suppression of
inflammation with treatment.
At present, liver biopsy is the gold standard for detecting
inflammation and fibrosis. Liver biopsy is commonly painful
and not without risks, although mortality is rare [16]. It would
be of great value to find novel non-invasive tools to assess
inflammation and fibrosis.
The aim of this prospective study was to show whether
31P MRS and TE detect inflammation and fibrosis in AIH




Twelve consecutive AIH patients, who had a liver biopsy with
clinical indications, were recruited into the study at Helsinki
University Hospital, Department of gastroenterology. We
used Simplified criteria for the diagnosis of autoimmune
hepatitis [17], and patients with both a definite or a probable
diagnosis were included, since 2008 criteria have been shown
to be fairly exclusive, and the disease behaviour in both
groups has been shown to be similar [17–19].
Methods
TE with FibroscanVR (Echosens, France) examinations were
done by one radiologist, who used a traditional ultrasound
probe in association with a TE probe to confirm the location
of the measurements in the liver parenchyma. The results
were based on a median of ten successful measurements. TE
results with an interquartile range below 30% of the median
value and a success rate of at least 60% were accepted
according to the manufacturer’s recommendations.
Liver biopsies were evaluated by the same pathologist
(SB), who scored the biopsies of all patients according to the
Metavir classification regarding inflammatory activity and
fibrosis. The Metavir and Ishak scoring systems have been
shown to correlate well with necroinflammatory changes and
fibrosis [20].
Biopsy, blood samples, TE and 31P MRS were performed
within a one-month period and before treatment was
changed.
Alanine aminotransferase (ALT), aspartate aminotransferase
(AST), immunoglobulin G (IgG), alkaline phosphatase (ALP),
thromboplastin time (TT) and albumin (Alb) were measured.
31P MRS of the liver was performed on a 3T clinical imager
(Achieva, Philips Medical Systems, Best, the Netherlands) with
subjects lying in a supine position. T1-weighted ultrafast gra-
dient echo images were collected in three orthogonal direc-
tions with 10mm slice thickness in the upper abdomen. The
number of slices was individually adjusted to cover the
whole liver. Images were collected during end-exhalation
breath holds. A 125–216 cm3 voxel was placed in the centre
of the right liver lobe using image selective in vivo spectros-
copy with TR of 6000ms and 128 acquisitions and using pro-
ton decoupling and nuclear Overhauser enhancement (NOE)
as previously described [6]. 31P MRS data were collected with
a circular non-flexible 31P transmit-receive loop coil with a
diameter of 14 cm, while the 1H body coil was used for pro-
ton decoupling and NOE during data acquisition. The sub-
jects were instructed to adjust their breathing cycle to the
pulse sequence noise, so that the excitation pulse and data
acquisition were timed to end exhalation. Breathing was
monitored using a standard navigator belt. The spectra were
analysed with jMRUI v5.0 software [21]. Intensities of phos-
phoetanolamine (PE), phosphocholine (PC), phosphorus (Pi),
glyserophosphoethanolamine (GPE), glycerophosphocholine
(GPC), phosphoenolpyruvate/phosphatidylcholine (PEP/PtdC),
a-, b-, and l-nucleotide triphosphate (NTP), nicotinamide
adenine dinucleotide phosphate (NADPH) and uridine
diphosphoglucose (UDPG) were determined using an
AMARES algorithm with prior knowledge [22]. Intensities
were expressed as a ratio to the total phosphorus signal.
Total phosphomonoester level (PME) and total phospho-
diester level (PDE) intensities were calculated from individual
signal components, while PME comprises PE and PC, while
PDE is the sum of GPE and GPC.
The study was approved by the Ethics Committee,
Department of Medicine, Helsinki University Hospital (diary
number 150/13/03/01/2012), and all subjects gave their writ-
ten informed consent. The study protocol conforms to the
ethical guidelines of the 1975 Declaration of Helsinki (6th
revision, 2008) as reflected in a priori approval by the institu-
tion's human research committee.
Statistics
The Pearson correlation coefficient for parametric tests and
the Spearman rank correlation coefficient for nonparametric
tests correlation were used in comparing between the
biopsy, 31P MRS, TE and laboratory tests. A two-tailed t-test
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for unpaired samples was used to compare the means
between two groups. p< .05 was considered statistically sig-
nificant. Statistical analyses were performed with SPSS v 22
(IBM corp, NY), SAS (SAS institute, NC).
Results
Patient characteristics and liver histology are described in
Tables 1 and 2. Examples of normal and abnormal (grade 2,
stage 2). AIH liver spectra and histology are shown in
Figure 1. The mean age of patients was 42.8 years. Most
were women (10/12), and seven out of 12 were in serological
remission. All were non-cirrhotic.
PEP correlated with histological inflammation grade
(r¼ 0.746, p¼ .005), TT (r¼ 0.592, p¼ .043 and ALP (r¼ 0.598,
p¼ .040). PEP was able to differentiate patients with active
histological inflammation (G1-3) from patients with none (G0)
(t¼ 3.781, p¼ .009) (Figure 2). PEP levels >0.35 had a sensi-
tivity of 100% (95%CI: 54.1–100%), specificity of 66.7%
(95%CI: 22.3–96.7%), positive predictive value (PPV) of 75%
(95%CI: 34.9–96.8%) and negative predictive value (NPV) of
100% (95%CI: 39.8–100%) to differentiate active inflammation
(G1-3) from patients with none.
PE/PC (Figure 3), PE/GPE and PC/(PMEþ PDE) ratios corre-
lated with inflammation activity as measured with IgG
(r¼ 0.764, p¼ .006; r¼ 0.618, p¼ .043; and r¼0.636,
p¼ .035, respectively). PE/PC and PE/GPE also separated
patients with elevated IgG (>15.0) from patients with normal
IgG (t¼ 2.233, p¼ .0496 and t¼ 2.672, p¼ .023, respectively).
PE/PC had sensitivity of 80% (95%CI: 28.4–99.5%), specificity
of 85.7 (95%CI: 42.1–99.6), PPV of 80% (95%CI: 28.4–99.5%)
and NPV of 85.7% (95%CI: 42.1–99.6%) with ratios of >2 and
PE/GPE 75% (95%CI: 19.4–99.4%), 87.5% (95%CI: 44.7–99.7%),
75% (95%CI: 19.4–99.4%) and 75% (95%CI: 19.4–99.4%) with
a ratio of >6, respectively, for detecting patients with ele-
vated IgG.
PME/PDE and PE/GPE correlated with fibrosis score
(r¼ 0.668, p¼ .018 and r¼ 0.604, p¼ .037, respectively
(Figures 4,5.). PE/GPE also differentiated patients with fibrosis
F3 from patients with no or mild fibrosis (F0-2) (t¼ 3.810,
p¼ .003) but could not differentiate patients with milder
fibrosis (between stages 1–2) from patients with no fibrosis
(F0). Sensitivity of PE/GPE for differentiating F3 from F0-2 was
100% (95%CI: 39.8–100%), specificity 50% (95%CI:
15.7–84.3%), PPV 50% (95%CI: 15.7–84.3) and NPV 100%
(95%CI: 39.8–100%) with 0.5 cut-off. With a cut-off of 0.7, the
values were 50% (95%CI: 6.8–93.2%), 100% (95%CI:
63.1–100%), 100% (95%CI: 15.8–100%) and 80% (95%CI:
44.4–97.5%).
The histological inflammation correlated with ALT and TT
(r¼ 0.767, p¼ .004 and r¼ 0.725, p¼ .008, respectively), but
not with IgG.
The median TE result was 6.1 kilopascals, range 3.0–10.8.
Compared to histology, TE overestimated fibrosis in two
patients and underestimated fibrosis in four patients. There
was no correlation between phosphorus metabolites and TE
or aminotransferase levels. TE did not correlate with phos-
phorus metabolites, liver histology or laboratory parameters.
Discussion
In the present study, we demonstrated that 31phosphorus
magnetic resonance spectroscopy of the liver is sensitive to
inflammatory changes and fibrosis in autoimmune hepatitis
patients. While it has previously been shown that 31P MRS
operates well in fatty liver disease, alcoholic liver disease and
hepatitis C [6,7,23], this has been demonstrated in auto-
immune liver diseases.
PEP was shown to be a sensitive marker for hepatitis
activity already at grade 1. PEP starts to rise early with histo-
logical inflammatory activity and can separate active hepatitis
from inactive state. Since PtdC behaves similarly to PEP in
the spectrum, there is a concern that we might have been
measuring PtdC instead of PEP. We reanalysed the biopsies
after this finding to look for bile duct damage in histology
but found only occasional mild cholangitis. ALP levels were
also normal in all patients.
PME (cell membrane precursors) to PDE (cell membrane
degradation products) ratio has previously been shown to
correlate with the presence of fibrosis and also fibrosis pro-
gression (anabolic charge) [8,9]. As a new finding, PE (sub-
group of PME) to GPE (subgroup of PDE) ratio correlated
with fibrosis. The PE/PGE ratio was also able to identify pre-
Table 2. Inflammation and fibrosis evaluated by
Metavir score [11] and macrovesicular steatosis
was evaluated at a medium power from haema-

















Table 1. Patient characteristics (n¼ 12).
Age mean years (range) 42.8 (19.6–69.1)
Time from diagnosis years mean (SD) 6.2 (3.1)
Women n 10
ALT median U/L (IQR) 28.5 (17.0–44.3)
Patients with elevated ALT (>45 U/L) n 3
ALP median U/L (IQR) 58.0 (45–89.3)
Patients with elevated ALP (>105 U/L) n 0
AST median U/L (IQR) 29.0 (24–37)
Patients with elevated AST (>35 U/L) n 2
IgG median g/L (IQR) 11.9 (11.0–18.5)
Patients with elevated IgG (>15 g/L) n 5
TT mean percent (SD) 98.0 (20.9)
Patients with decreased TT (<70%) n 0
Overlapping primary biliary cirrhosis n 2
Patients in serological remission 7
ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate ami-
notransferase; g: gram; IgG: immunoglobulin G; n: number; IQR: interquartile
range; L: litre; SD: standard deviation; U: unit; TT: Thromboplastin time.
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Figure 2. Phosphoenolpyruvate in three groups of inflammation.
Figure 1. Illustrative spectra and histology of two AIH patients with different stages of liver disease.
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cirrhotic patients (F3) from patients with only mild or moder-
ate fibrosis. MRS cannot separate these subcomponents at
1.5 T strength without proton decoupling. However, proton
decoupling with a 31P nucleus with at 3T, is now able to do
so. Similar to a previous study [9], in our patients, changes in
the phosphorus spectrum seem to develop rather late during
fibrosis progression.
In our patients, transient elastography was not effective in
the evaluation of fibrosis. It is possible that the study mater-
ial was too small to find any correlations. A more probable
explanation is that TE does not show fibrosis in AIH patients
correctly. TE has not been validated in published studies in
AIH patients. Also, inflammation has been shown to elevate
measured TE values [14,15].
Patients in the study had variable degrees of inflammation
in the liver categorised by histology, but laboratory values,
especially ALT and AST levels, were normal or only mildly
increased, and there was little variance throughout the study
population to find any statistical correlation with the MRI
spectrum. However, ALT levels correlated with histological
Figure 4. Phosphoenolate/glyserophosphoethanolamine ratio elevation is a sign of advanced fibrosis.
Figure 3. Phosphoetanolamine/phosphocholine ratio as a function of immunoglobulin G.
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inflammation. IgG, as a marker of inflammation, correlated
with 31P MRS.
Liver biopsy is still needed for the diagnosis of AIH. 31P
MRS could be used in the follow-up of patients who refuse
liver biopsy or in whom biopsy is contraindicated. 31P MRS
provides information of both inflammation and fibrosis, with
different markers for either parameter.
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